About US
Contact us
-
Court tosses Praluent ban, gives Sanofi and Regeneron a new trial in Amgen patent battleAn appeals court today tossed out a ban on Sanofi’s and Regeneron’s cholesterol drug Praluent and is giving the partners a second chance to prove they didn’t trample on Amgen patents in its developmen2017/9/30
-
Sanofi and Regeneron, seeking to shield Dupixent, lose first IPR try against AmgenTo defend against Amgen’s claim that Sanofi and Regeneron had infringed one of its patents with new atopic dermatitis rollout Dupixent, the development partners went the inter partes review route to t2017/9/30
-
Most new cancer meds haven't proved they can improve or extend lives: studySixty-eight cancer drug indications won European approval between 2009 and 2013—but most of them did so without showing they could extend or improve life, a new study shows. According toresultspubl2017/9/29
-
Pharma's legal challenge to U.K. cost clampdown gets shot downPharmaceutical companies, which have taken a hard stance against new cost-management strategies in England,have fallen short in an effort to block them with a legal challenge. The Association o2017/9/29
-
EMA unveils staffers' preferences for agency move: Amsterdam gets a yes, Warsaw a noWould you want to live in Barcelona, Amsterdam, Copenhagen, Milan or Vienna? Staffers of the European Medicines Agency would—or at least those are their top picks for an agencymove after Brexit. Lot2017/9/28
-
Backlash to Allergan's tribal patent deal builds as House lawmakers launch probeAfter five senators came out against the company's tribal licensing deal and Allergan CEO Brent Saunders took a chance to respond, the drugmaker's patent defense strategy is drawing even more attent2017/9/28
-
Gilead offers its newest HIV drug candidate to patent pool for low-cost productionGilead Sciences is licensing its newest HIV drug candidate, bictegravir,to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income cou2017/9/27
-
Mylan surprises analysts, Teva with long-delayed Copaxone approvalsMylan’s long been frustrated by delays for a pair of high-profile generic products. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense. The FDAgreenlight2017/9/27
-
Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead linesAllergan’s Botox, which the company has called a “pipeline in a drug,” has delivered again.On Tuesday, the FDAapprovedthe blockbuster product to temporarily improve the appearance of certain forehead2017/9/26
-
As Eli Lilly moves some marketing in-house, should ad agencies brace for fallout?Eli Lilly is moving to a new marketing model as part of its corporatepush to manage expenses, but what does that mean for its advertising and marketing agency partners? So far, no one is saying exactl2017/9/26